PHC Holdings (6523) · InitiativeAchieved
Accelerating POCT Growth through the Integration of PHC and LSIM’s Diagnostic Reagent Businesses
First written in FY2024-Q1. 1 of 2 entries say "Achieved", first in FY2024. Latest entry: FY2024.
2entries
2years
0from disclosures
How it moved
Same theme, other companies
Functional Integration and Domain Expansion through Reorganization within the Healthcare BusinessA theme 10 companies write about · 0 as a headwind · 10 as a tailwind
2 other companies' latest entry also says "Achieved".
Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Full recordFilings, disclosures and news, newest first
- FY2024AchievedAnnual report
「On 1 November 2023, the diagnostics and instruments business of LSIM was transferred to the Diagnostics Business Division of PHC株式会社.」
The PHC and LSIM diagnostics businesses were integrated on 1 November 2023. Following the integration, the company plans to pursue higher quality and lower costs, develop instruments and reagents, expand overseas sales, and strengthen its ability to make proposals to key customers. - FY2024-Q1First statedAnnual report
「Since LSIM joined the PHC Group in 2019, the PHC and LSIM diagnostics businesses had coexisted within the Group. We will integrate the two businesses and further accelerate the growth of the diagnostics business, centered on POCT, which is positioned as a growth area in our medium-term management plan, "Value Creation Plan(FY22-FY25)".」
The company announced plans to integrate the PHC and LSIM diagnostics businesses and, centered on POCT, which is designated as a growth area in the medium-term management plan, pursue higher product quality and lower costs, develop instruments and reagents, expand overseas sales, and strengthen its ability to make proposals to key customers.